CN106572910B - Mitral valve implant for treating valvular regurgitation - Google Patents

Mitral valve implant for treating valvular regurgitation Download PDF

Info

Publication number
CN106572910B
CN106572910B CN201580044329.0A CN201580044329A CN106572910B CN 106572910 B CN106572910 B CN 106572910B CN 201580044329 A CN201580044329 A CN 201580044329A CN 106572910 B CN106572910 B CN 106572910B
Authority
CN
China
Prior art keywords
anchor
coaptation
implant
assistance device
coaptation assistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580044329.0A
Other languages
Chinese (zh)
Other versions
CN106572910A (en
Inventor
亚历山大·K·海尔哈汗
迈克尔·D·莱什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boraris Medical Co ltd
Original Assignee
Boraris Medical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boraris Medical Co ltd filed Critical Boraris Medical Co ltd
Priority to CN202110375324.3A priority Critical patent/CN113081393A/en
Priority claimed from PCT/US2015/036260 external-priority patent/WO2015195823A1/en
Publication of CN106572910A publication Critical patent/CN106572910A/en
Application granted granted Critical
Publication of CN106572910B publication Critical patent/CN106572910B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Prostheses (AREA)

Abstract

The present invention relates in some aspects to devices for use in transcatheter treatment of mitral valve regurgitation, including steerable guide wires, implantable coaptation assistance devices, anchoring systems for attaching ventricular projections of implantable coaptation devices, kits, and methods of using implantable coaptation assistance devices.

Description

Mitral valve implant for treating valvular regurgitation
The present application claims priority from U.S. provisional patent application No. 62/014060 entitled "mitral valve implant for treating valvular regurgitation" filed 6/18 2014. The entire disclosure of the prior priority application is incorporated herein by reference for all purposes.
Background
FIELD
The present invention generally provides improved medical devices, systems and methods typically for treating heart valve disease and/or for altering the characteristics of one or more valves of the body. Embodiments of the invention include an implant for treating mitral regurgitation.
The human heart receives blood from organs and tissues via veins, pumps the blood through the lungs where it becomes oxygen-rich, and pushes the oxygenated blood away from the heart to arteries so that the body's organ system can extract oxygen for proper function. The deoxygenated blood flows back to the heart where it is pumped again to the lungs.
The heart includes four chambers: the Right Atrium (RA), Right Ventricle (RV), Left Atrium (LA) and Left Ventricle (LV). The pumping action on the left and right sides of the heart occurs generally synchronously during the overall cardiac cycle.
The heart has four valves that are typically configured to selectively deliver blood flow in the correct direction during the cardiac cycle. The valve that separates the atrium from the ventricle is called the atrioventricular (or AV) valve. The AV valve between the left atrium and left ventricle is the mitral valve. The AV valve between the right atrium and right ventricle is the tricuspid valve. The pulmonary valve directs blood flow to the pulmonary arteries and thence to the lungs; the blood returns to the left atrium via the pulmonary veins. The aortic valve directs blood flow through the aorta and thence to the periphery. There is usually no direct connection between the ventricles or between the atria.
Mechanical heart beats are triggered by electrical impulses that propagate throughout the heart tissue. The opening and closing of the heart valve may occur primarily due to pressure differences between the chambers, which may result from passive filling or chamber contraction. For example, opening and closing of the mitral valve may occur due to a pressure difference between the left atrium and the left ventricle.
At the beginning of ventricular filling (diastole), the aortic and pulmonary valves close to prevent backflow from the arteries into the ventricle. Immediately thereafter, the AV valve opens to allow unimpeded flow from the atria into the respective ventricles. Immediately after ventricular contraction (i.e., ventricular emptying) begins, the tricuspid and mitral valves typically close, forming a seal that prevents flow from the ventricles back into the respective atria.
Unfortunately, the AV valve may be damaged or may not function properly, resulting in an abnormal closure. AV valves are complex structures that typically include the annulus (annuus), leaflets (leaflets), chordae (chord), and support structures. Each atrium is connected to its valves via the atrial vestibulum. The mitral valve has two leaflets; a similar structure of the tricuspid valve has three leaflets, and the opposition or coaptation of the respective leaflet surfaces toward each other helps provide closure or sealing of the valve to prevent blood flow in the wrong direction. Failure of the leaflets to seal during ventricular systole is known as poor coaptation and may allow blood to flow back through the valve (regurgitation). Heart valve regurgitation can have serious consequences for the patient, often resulting in heart failure, reduced blood flow, low blood pressure, and/or reduced oxygen flow to body tissues. Mitral regurgitation can also cause blood to flow back from the left atrium into the pulmonary veins, causing congestion. Severe valve regurgitation, if left untreated, can result in permanent disability or death.
Description of the related Art
Various therapies have been applied to treat mitral valve regurgitation, and other therapies have still been proposed but have not been practically used to treat patients. While several known therapies have been found to provide benefits to at least some patients, further options are still needed. For example, medicaments (such as diuretics and vasodilators) may be used in patients with mild mitral regurgitation to help reduce the amount of blood that regurgitates into the left atrium. However, medication may lack patient compliance. Many patients may occasionally (or even regularly) fail medication despite the potential severity of chronic and/or increasingly worsening mitral regurgitation. Pharmacological treatment of mitral regurgitation can also be inconvenient, often ineffective (especially as the situation worsens), and may be associated with serious side effects (such as hypotension).
Various surgical options have also been proposed and/or used to treat mitral regurgitation. For example, open-heart surgery (open-heart surgery) may replace or repair a dysfunctional mitral valve. In annuloplasty (annuloplasty) annuloplasty annular repair, the posterior mitral annulus may be reduced in size along its circumference, optionally suturing the annulus with sutures by mechanical surgical annuloplasty to provide coaptation. Open surgery may also seek to reshape the leaflets and/or remodel the support structure. In any event, open mitral valve surgery (open mitral valve surgery) is generally a very invasive treatment that is performed on a cardiopulmonary machine with the patient under general anesthesia and the chest being cut. Complications can be common and given the morbidity (and potential mortality) of open-heart surgery, scheduling becomes a difficult problem-more ill patients may require surgery at best, but are less able to survive surgery. Successful open mitral valve surgery results can also be very dependent on surgical skill and experience.
In view of morbidity and mortality from open-heart surgery, innovators have sought less invasive surgical therapies. Methods performed robotically or by endoscopy are still often quite invasive and can also be time consuming, expensive, and, in at least some cases, highly dependent on the skill of the surgeon. It would be desirable to make even less traumatic to these sometimes infirm patients, and it would also be desirable to provide a therapy that can be successfully administered by a large number of physicians using a widely varying technique. To this end, a variety of techniques and methods have been proposed which are said to be less invasive. These include devices that seek to reshape the mitral annulus from within the coronary sinus; devices that attempt to reshape the annulus by tying the native valve ring from top to bottom; a device to fuse leaflets (mimicking an alfiri suture); devices that reshape the left ventricle, etc.
A variety of perhaps the best known mitral valve replacement implants have been developed that generally replace (or displace) the native leaflets and rely on surgically implanted structures to control the blood flow path between heart chambers. While these various methods and tools meet various levels of certainty, none have been widely recognized as an ideal treatment for most or all patients suffering from mitral regurgitation.
Due to the difficulties and disadvantages of known minimally invasive mitral valve regurgitation therapies and implants, still alternative treatments have been proposed. Some alternative proposals require the implanted structure to remain within the annulus throughout the heart cycle. One group of these proposals includes cylindrical balloons or the like that remain implanted on a cord or rigid rod that extends between the atrium and ventricle through the valve opening. Another group relies on arcuate ring structures or the like, often in combination with structural cross members or buttons extending through the wall of the valve to secure the implant. Unfortunately, sealing between the native leaflets and the entire perimeter of the balloon or other coaxial body can prove challenging, while significant contraction around the native annulus during each heartbeat can lead to significant fatigue failure tissue during long-term implantation if the arch wall or fixator interconnecting cross-members are allowed to flex. Furthermore, significant movement of the valve tissue can make accurate positioning of the implant difficult, regardless of whether the implant is rigid or flexible.
In view of the above, it is desirable to provide improved medical devices, systems and methods. It would be particularly desirable to provide new techniques for treating mitral regurgitation and other heart valve diseases, and/or for altering the characteristics of one or more of the other valves of the body. There remains a need for a device that can directly augment leaflet coaptation via fusion or other means (rather than indirectly via annular or ventricular reshaping) and that does not disrupt leaflet anatomy, but that can be simply and reliably deployed and that does not require excessive cost or procedure time. It would be particularly advantageous if these new techniques could be implemented using less invasive methods, without the need to stop the heart or rely on heart-lung machines for deployment, and without the need to rely on the expertise of the surgeon, thereby providing improved valve and/or heart function.
SUMMARY
In some embodiments, disclosed herein is an implant for treating cardiac valve insufficiency. The implant may include one or more of the following: a shape memory structure, a biocompatible membrane coupled to the structure, a hub (hub) placed on a proximal side of the implant and coupled to the membrane, one, two or more holes or perforations along an edge of the membrane on the proximal side, and a ventricular projection coupled to an anchoring device. The implant may be folded for delivery through a percutaneous catheter. The shape memory structure may comprise a shape memory spine (spine), such as nitinol or, for example, PEEK. A portion of the ventricular projection, such as the distal tip, may be radiopaque. The anchoring means may be active or passive. The ridges may include features such as micro-holes and micro-hooks for attachment to the membrane and tissue.
Also disclosed herein is a steerable catheter comprising one or more of a steerable shaft, a rotatable handle coupled to a pull wire placed within the shaft to adjust a bend radius of a distal tip of the shaft as a function of an amount of torque applied to the handle. In some embodiments, the diameter of the handle of the catheter is equal to the diameter of the steerable shaft, or no greater than the diameter of the steerable shaft. Also disclosed herein is a delivery catheter comprising one or more of the following: a rotatable handle coupled to a pull wire placed within a twistable shaft to adjust a bend radius of a distal tip of the shaft of the catheter, a sheath designed to house the implant when the implant is folded, and a distal tip further comprising a locking component capable of connecting a delivery catheter to a hub (hub) of an implant or to an anchor. In some embodiments, the catheter may further include a tearable disposable funnel to assist in folding of the implant. In some embodiments, the distal tip further comprises a locking tab that is naturally disposed in an unlocked position. The delivery catheter may be coupled to an annular hub (annular hub) of the implant having a feature that receives a locking tab of the delivery catheter. In some embodiments, a guide wire or other catheter may be inserted within the shaft to push a locking tab toward a mating feature on a hub of the implant so that the catheter and hub are locked. The catheter may also include a loop, such as a wire that travels from the proximal handle to the distal tip so that tension in the loop can be controlled via controls on the handle. The delivery catheter may be coupled to an annulus hub of the implant, the annulus hub having a cross pin. A guide wire or other catheter may be inserted within the shaft and the wire loop tightened against the cross pin and guide wire until tension on the loop is maintained, such that the delivery catheter locks to the hub of the implant.
The implant may be operably coupled to a tissue, such as cardiac tissue, via a first coupling of the anchor to the delivery catheter and a second coupling of the anchor to the implant hub, wherein a torque is applied to the delivery catheter to insert the anchor into the hub and the tissue. The first coupling may be uncoupled to withdraw the catheter.
In some embodiments, a commissure anchor may be delivered by one or more of the following steps: coupling an anchor to a shaft of a catheter, advancing the anchor and the catheter to an anchoring site, delivering the anchor such that it engages with an implant and tissue, and decoupling the anchor from the shaft. The shaft may be torqueable, and an engagement mechanism may apply torque to the shaft such that the anchor engages the implant and tissue. The anchor may be made of a shape memory material and may be compressed into a shaft of a catheter for delivery to an anchoring site, wherein a distal tip of the catheter is shaped such that it pierces tissue. The anchor can be advanced after the delivery catheter first pierces the tissue, and the catheter subsequently retracted, leaving the anchor in place.
In some embodiments, an implant for treating cardiac valve insufficiency is disclosed. The implant may include one or more of the following: a removable shape memory structure, a biocompatible membrane coupled to the structure, a hub placed on a proximal side of the implant and coupled to the membrane, one, two or more holes or perforations along an edge of the membrane on the proximal side, and a ventricular projection coupled to an anchoring device. The implant may also include at least one passageway, such as a passageway placed around the edge of the annulus and/or along a ventricular projection. In some embodiments, multiple, such as 2, 3, 4, 5, or more anchors are delivered to couple the implant to the cardiac tissue. The delivery device may have a distal segment comprising 1, 2, or more anchors rotatably coupled to a central rotating shaft. The spring-loaded mechanism may exert a pushing force to cause the anchor to exit the distal end. In some embodiments, the anchor may be housed in a housing with a groove on the inner diameter such that the anchor may exit the distal end as the central rotating shaft rotates. The apparatus may comprise one or more of the following, for example: a hollow shaft, a pointed tip at the end of the hollow shaft, one, two or more hollow barrels placed within the hollow shaft through which the wire passes, and a push rod at the proximal end, such that when force is applied to the push rod, the barrels exit the hollow shaft one after another.
In some embodiments, disclosed herein is a steerable guidewire comprising an elongate flexible body having a longitudinal axis, a proximal end, and a distal deflection zone; a control on the proximal end for controllable deflection of the deflection zone; and a movable deflection element extending from the control member toward the deflection zone. In some embodiments, no portion of the guidewire has an outer diameter greater than about 10 french, 8 french, 6 french, or 4 french. The control member may have an outer diameter that is no greater than an outer diameter of the body. Rotation of the control member about the axis may cause lateral movement of the deflection zone. Rotation of the control member about the shaft in a first direction may cause proximal retraction of the deflecting element.
Also disclosed herein is an implantable coaptation assistance device comprising a flexible body; a first concave surface on the body configured to restrain a posterior leaflet; a second concave surface on the body configured to contact an anterior leaflet; an arcuate peripheral upper edge on the body, the arcuate peripheral upper edge defining an opening facing away from the first surface; and a ventricular projection extending away from the body and configured to be anchored in a ventricle. The device may also include an anchor on the ventricular projection. The anchors may be active or passive. The device may further include a flexible ridge for supporting the arcuate peripheral edge. In some cases the ridges may be removable.
Also disclosed herein is an anchoring system for attaching a ventricular projection of an implantable coaptation device. The system may include: a shoulder having a bore extending therethrough; a helical tissue anchor extending distally from a hub; a first engagement structure on the anchor for releasably engaging a torque shaft; a second engagement structure on the torque shaft for engaging the anchor; and an implant having a hub sized to receive the helical anchor therethrough; wherein the torque shaft is configured to rotate to drive the helical anchor into tissue and secure the implant to tissue. The first engagement structure may be an aperture and the second engagement structure may be a protrusion. The protrusion may be laterally movable into and out of the aperture, such as in response to axial movement of an elongate element within the torque shaft.
In some embodiments, a steerable guidewire is provided. The steerable guidewire may include an elongated flexible body having a longitudinal axis, a proximal end, and a distal deflection zone. The steerable guidewire may include controls on the proximal end for controllable deflection of the deflection zone. The steerable guidewire may include a movable deflection element extending from the control toward the deflection region. In some embodiments, no portion of the guidewire has an outer diameter greater than about 10 french. In some embodiments, no portion of the guidewire has an outer diameter greater than about 6 french. In some embodiments, no portion of the guidewire has an outer diameter greater than about 4 french. In some embodiments, the control member has an outer diameter that is no greater than an outer diameter of the body. In some embodiments, rotation of the control about the axis causes lateral movement of the deflection zone. In some embodiments, rotation of the control in a first direction about the shaft causes proximal retraction of the deflecting element.
In some embodiments, an implantable coaptation assistance device is provided. The implantable coaptation assistance device can include a flexible body. The implantable coaptation assistance device can include a first concave surface on the body configured to restrain a posterior leaflet. The implantable coaptation assistance device can include a second concave surface on the body configured to contact an anterior leaflet. The implantable coaptation assistance device can include an arcuate peripheral superior edge on the body that defines an opening facing away from the first surface. The implantable coaptation assistance device can include a ventricular projection extending away from the body and configured to anchor in the ventricle.
In some embodiments, the implantable coaptation assistance device can include an anchor on the ventricular projection. In some embodiments, the implantable coaptation assistance device can include an active anchor. In some embodiments, the implantable coaptation assistance device can include a passive anchor. In some embodiments, the implantable coaptation assistance device can include a flexible ridge for supporting the arcuate peripheral edge. In some embodiments, the ridge is removable.
In some embodiments, an anchoring system for attaching a ventricular projection of an implantable coaptation device is provided. The anchoring system may include a shoulder having a bore extending therethrough. The anchoring system may include a helical tissue anchor extending distally from a hub. The anchoring system may include a first engagement structure on the anchor for releasably engaging a torque shaft. The anchoring system may include a second engagement structure on the torque shaft for engaging the anchor. The anchoring system may include an implant having a hub sized to receive the helical anchor therethrough. In some embodiments, the torque shaft is configured to rotate to drive the helical anchor into tissue and secure the implant to tissue. In some embodiments, the first engagement structure is a hole and the second engagement structure is a protrusion. In some embodiments, the protrusion is laterally movable into and out of the aperture. In some embodiments, the protrusion is laterally movable into and out of the aperture in response to axial movement of an elongate element within the torque shaft.
In some embodiments, an implantable coaptation assistance device is provided. The implantable coaptation assistance device can include a coaptation assistance body including a first coaptation surface, an opposing second coaptation surface, each surface bounded by a first lateral edge, a second lateral edge, a lower edge, and an upper edge. The implantable coaptation assistance device can include a ventricular projection extending from the inferior edge. The implantable coaptation assistance device can include a first support extending through at least a portion of the coaptation assistance device between the superior edge and the ventricular projection. The implantable coaptation assistance device can include a second support extending through at least a portion of the coaptation assistance body between the first lateral edge and the second lateral edge. The implantable coaptation assistance device can include a passageway extending through at least a portion of the coaptation assistance device, the passageway sized to receive a steerable catheter therethrough. In some embodiments, the first support has a first configuration in which the first support is substantially linear and a second configuration in which the first support is curved. In some embodiments, the first and second supports are configured to allow percutaneous insertion of the implantable coaptation assistance device.
In some embodiments, the passageway extends through at least a portion of the coaptation assistance device between the superior edge and the ventricular projection. In some embodiments, the steerable catheter comprises a distal tip configured to bend. In some embodiments, rotating the handle of the steerable catheter causes the distal tip to bend. In some embodiments, the first support comprises a shape memory material. In some embodiments, the first support is bonded to the coaptation assist body. In some embodiments, the coaptation assistance body includes a lumen sized to receive at least a portion of the first support. In some embodiments, the first support is removable. In some embodiments, the first support extends from the superior edge to the ventricular projection. In some embodiments, the passageway extends through at least a portion of the coaptation assist body between the first lateral edge and the second lateral edge. In some embodiments, the second support comprises a shape memory material. In some embodiments, the second support is bonded to the coaptation assist body. In some embodiments, the coaptation assist body comprises a lumen sized to receive at least a portion of the second buttress. In some embodiments, the second support is removable. In some embodiments, the second support extends from the first lateral edge to the second lateral edge. In some embodiments, the first support is coupled to the second support. In some embodiments, the first support and the second support are coupled to a removable hub that protrudes from a surface of the coaptation assist body.
In some embodiments, a kit is provided. The kit may include an implantable coaptation assistance device. The implantable coaptation assistance device can include a coaptation assistance body including a first coaptation surface, an opposing second coaptation surface, each surface bounded by a first lateral edge, a second lateral edge, a lower edge, and an upper edge. The implantable coaptation assistance device can include a ventricular projection extending from the inferior edge. The implantable coaptation assistance device can include a passageway extending through at least a portion of the coaptation assistance device, the passageway sized to receive a steerable catheter therethrough. The kit may include a steerable catheter. In some embodiments, the steerable catheter is configured to pass through the mitral valve and curve toward ventricular tissue, wherein the implantable coaptation assistance device is configured to be passed through the steerable catheter toward the ventricular tissue.
In some embodiments, the passageway extends through at least a portion of the coaptation assistance device between the superior edge and the ventricular projection. In some embodiments, the steerable catheter comprises a distal tip configured to bend. In some embodiments, rotating the handle of the steerable catheter causes the distal tip to bend. In some embodiments, the passageway extends through at least a portion of the coaptation assist body between the first lateral edge and the second lateral edge.
In some embodiments, methods of using an implantable coaptation assistance device are provided. The method can include the step of inserting a coaptation assist body toward the heart valve. In some embodiments, the coaptation assist body includes a first coaptation surface, an opposing second coaptation surface, each surface bounded by a first lateral edge, a second lateral edge, a lower edge, and an upper edge, a ventricular projection extending from the lower edge. The method can include the step of manipulating the first support to cause the coaptation assist body to assume a curved configuration. In some embodiments, the first support extends through at least a portion of the coaptation assistance device between the superior edge and the ventricular projection. The method can include the step of manipulating a second support to cause the coaptation assist body to assume a curved configuration. In some embodiments, the second support extends through at least a portion of the coaptation assist body between the first lateral edge and the second lateral edge.
In some embodiments, manipulating the first support comprises releasing the coaptation assist body from the delivery catheter. In some embodiments, manipulating the second support comprises releasing the coaptation assist body from the delivery catheter. The method can include the step of guiding the coaptation assist body through a steerable catheter. The method may include the step of passing a steerable catheter from the ventricular projection toward the superior rim prior to inserting the coaptation assist body toward the heart valve. The method can include the step of moving a distal portion of the steerable catheter to curve around the posterior leaflet. The method can include the step of passing the coaptation assistance device through a curve of the steerable catheter. In some embodiments, the steerable catheter is removed after the ventricular projection engages ventricular tissue. In some embodiments, the steerable catheter is held in place while advancing the ventricular projection toward the ventricular tissue. The method may include the step of removing the first support from the coaptation assist body. The method may include the step of removing the second buttress from the coaptation assist body. The method may include the step of engaging the ventricular projection with ventricular tissue. In some embodiments, the method is performed transdermally.
Brief Description of Drawings
Fig. 1A-1F schematically illustrate some tissues of the heart and mitral valve, as described in the background section and below, and which may interact with the implants and systems described herein.
Fig. 2A illustrates a simplified cross-section of a heart, schematically showing mitral valve function during diastole.
Fig. 2B illustrates a simplified cross-section of a heart, schematically showing mitral valve function during systole.
Figures 3A-3B illustrate simplified cross-sections of a heart schematically showing mitral regurgitation during systole in the event of mitral insufficiency.
Fig. 4A illustrates a stylized cross-section of a heart showing mitral insufficiency with functional mitral regurgitation.
Fig. 4B illustrates a stylized cross-section of a heart showing mitral insufficiency in the event of degenerative mitral regurgitation.
Fig. 5A illustrates an embodiment of a coaptation assistance device.
FIG. 5B illustrates various cross-sections that the support structure may have along section A-A of FIG. 5A.
Fig. 5C illustrates various shapes of anchors at the distal end of ventricular projections.
Fig. 5D illustrates a non-limiting embodiment of a range of sizes of coaptation assistance devices.
Fig. 5E illustrates a table of non-limiting embodiments of various variations (materials, dimensional ranges) of the support structure.
Fig. 5F illustrates an embodiment of the distal end of a ventricular projection.
Fig. 5G illustrates that the position of the coaptation assistance device can be maintained by grasping the native valve leaflet with the shape of the coaptation assistance device.
Fig. 5H illustrates an embodiment of how the coaptation assistance device can be secured through the posterior leaflet from the ventricular side.
Fig. 6A illustrates a steerable catheter.
Fig. 6B illustrates the position of the steerable catheter of fig. 6A in the heart.
Fig. 7A illustrates a delivery catheter.
Fig. 7B illustrates an embodiment of a locking mechanism that locks the delivery catheter to the annulus hub.
Fig. 7C illustrates another embodiment of a locking mechanism that locks the delivery catheter to the annulus hub.
Fig. 7D illustrates the coupling of the coaptation assistance device, the delivery catheter, and the guidewire or steerable catheter.
Fig. 8A-8D illustrate how the coaptation assistance device folds and pulls in the implant sheath and is delivered to the heart through the femoral approach.
Fig. 8E-8G illustrate how the delivery catheter and implant sheath are placed so that the ventricular projection of the coaptation assistance device can be anchored.
Fig. 8H illustrates a fully open coaptation assistance device and a delivery catheter positioned over the annulus hub for anchoring the annulus hub to the annulus.
Fig. 8I illustrates an embodiment of an anchor that may be used to anchor the annulus hub.
Fig. 9A illustrates a method of anchoring a coaptation assistance device adjacent to the commissure via a hole in the frame of the coaptation assistance device.
Fig. 9B illustrates a top view of the anchor and cross-bar of fig. 9A.
Fig. 10A illustrates another embodiment of a delivery catheter having multiple lumens and connections to an implant.
Figure 10B illustrates a cross-section of the delivery catheter shown in figure 10A.
Fig. 11A-B illustrate various alternative embodiments of anchors.
Fig. 11C illustrates a delivery tube through which anchors 11A and 11B may be delivered.
Fig. 11D illustrates how the anchor of fig. 11B may look after the anchoring process is over.
Fig. 12 illustrates a no-spine implant design (shown here as structure 1220, which is later withdrawn from the implant).
Fig. 13A-B illustrate an initial stage of a delivery procedure for a spinal-free implant.
Fig. 14A-B illustrate various types of anchoring methods for a spinal-free implant.
Fig. 15A illustrates an embodiment of an anchoring catheter that enables delivery of multiple anchors. This figure also illustrates a multiple anchor design.
Fig. 15B illustrates another embodiment of an anchoring catheter that enables delivery of multiple anchors.
Fig. 15C-D illustrate how the anchor in 15B can be coupled to tissue.
Fig. 16A illustrates another embodiment of an anchoring catheter that enables delivery of multiple anchors.
Fig. 16B-C illustrate how the tool of fig. 16A can be used to deliver multiple anchors.
Fig. 17A illustrates another embodiment of a spinal-free implant.
Fig. 17B-E illustrate how the embodiment of fig. 17A may be anchored.
Detailed description of the invention
The devices, systems, and methods described within this disclosure are generally used to treat Mitral Regurgitation (MR). Mitral regurgitation occurs when the mitral valve fails to prevent blood from the left ventricle from flowing back into the left atrium during systole. The mitral valve consists of two leaflets, an anterior leaflet and a posterior leaflet, that coapt or meet during systole to prevent regurgitation. There are generally two types of mitral regurgitation, functional regurgitation and degenerative regurgitation. Functional MR is caused by a variety of mechanisms including abnormal or impaired Left Ventricular (LV) wall motion, left ventricular dilation, and papillary muscle disorders. Degenerative MR is caused by structural abnormalities of the valve leaflets and subvalvular tissue, including stretching or rupture of the chordae tendineae. Damaged chordae can lead to prolapse of the leaflets, which means that the leaflets protrude (usually into the atrium), or, if the chordae tear, become flails, leading to backflow of blood. As described below, the devices, systems, and methods of the present disclosure provide a new apposition surface over the native posterior leaflet such that backflow flow of blood is minimized or eliminated.
Referring to fig. 1A-1D, four chambers of the heart are shown, the left atrium 10, the right atrium 20, the left ventricle 30, and the right ventricle 40. The mitral valve 60 is disposed between the left atrium 10 and the left ventricle 30. Also shown are tricuspid valve 50 (which separates right atrium 20 from right ventricle 40), aortic valve 80, and pulmonary valve 70. The mitral valve 60 is composed of two leaflets (an anterior leaflet 12 and a posterior leaflet 14). In a healthy heart, the edges of the two leaflets oppose each other at the coaptation region 16 during systole.
The fibrous annulus 120, which is part of the heart frame, provides attachment for the two leaflets of the mitral valve, referred to as the anterior leaflet 12 and the posterior leaflet 14. The leaflets are axially supported by attachment to chordae tendineae 32. The cord is in turn attached to one or both of the papillary muscles 34, 36 of the left ventricle. In a healthy heart, the cable support structure tethers the mitral valve leaflets, allowing the leaflets to open easily during diastole, but tolerates the high pressures that develop during ventricular systole. In addition to the tethering effect of the support structure, the shape and tissue consistency of the leaflets help promote effective sealing or coaptation. The leading edges of the anterior and posterior leaflets meet along the coaptation region 16, where a cross-section 160 of the three-dimensional coaptation region (CZ) is schematically shown in fig. 1E.
The anterior and posterior mitral valve leaflets have different shapes. The anterior leaflet is more firmly attached to the annulus overlying the central fibrous body (the heart frame) and is somewhat stiffer than the posterior leaflet, which is attached to the more mobile posterior mitral annulus. About 80% of the occlusion area is the anterior leaflet. Left (lateral) 124 and right (septal) 126 fibrous trigones formed with the mitral annulus fused to the base of the non-coronary cusp (non-coronary cusp) of the aorta are positioned adjacent to the commissures 110, 114, above or in front of the annulus 120 (fig. 1F). The fibrous trigones 124, 126 form spaced extensions and lateral extensions of the central fibrous body 128. In some embodiments, the fibrous trigones 124, 126 may have advantages, such as providing a secure area for stable engagement with one or more annulus anchors (anchors) or atrial anchors. The coaptation region CL between the leaflets 12, 14 is not a simple line, but a curved, funnel-shaped surface interface. The commissures of the first 110 (lateral or left) and second 114 (septal or right) leaflets are where the anterior leaflet 12 meets the posterior leaflet 14 at the annulus 120. As best seen in the axial views of the atrium of fig. 1C, 1D and 1F, the axial cross-section of the coaptation region generally shows a curved line CL that is separated from the centroid of the annulus CA and from the opening through the valve during diastole CO. Furthermore, the leaflet edges have rounded teeth, especially in the posterior leaflet compared to the anterior leaflet. Incompetence may occur between one or more of these a-P (anterior-posterior) segment pairs a1/P1, a2/P2, and A3/P3, such that incompetence characteristics may vary along the curve of the coaptation region CL.
Referring now to fig. 2A, a properly functioning mitral valve 60 of the heart is open during diastole to allow blood to flow along a flow path FP from the left atrium to the left ventricle 30 and thereby fill the left ventricle. As shown in fig. 2B, by increasing ventricular pressure, first passively then actively, the functioning mitral valve 60 closes during systole and effectively separates the left ventricle 30 from the left atrium 10, thereby allowing the heart tissue surrounding the left ventricle to contract to push blood through the vascular system.
Referring to fig. 3A-3B and 4A-4B, there are several conditions or disease states in which the leaflet edges of the mitral valve do not oppose sufficiently and thereby allow blood to flow from the ventricles back into the atria during the systolic phase. Regardless of the specific etiology of a particular patient, the failure of the leaflets to seal during ventricular systole is known as insufficiency and causes mitral regurgitation.
In general, insufficiency may be caused by over-tethering of the support structure of one or both leaflets, or may be caused by over-stretching or tearing of the support structure. Other less common causes include heart valve infections, congenital abnormalities, and trauma. Valve dysfunction can be caused by: the chordae tendineae are stretched (known as mitral valve prolapse), and in some cases, tears of the chordae tendineae 215 or papillary muscles (known as flail leaflets 220), as shown in fig. 3A. Alternatively, if the leaflet tissue itself is redundant, the valve may prolapse such that coaptation occurs at a higher level into the atrium, opening the valve higher in the atrium 230 during ventricular systole. Any of the leaflets may prolapse or become flail. This condition is sometimes referred to as degenerative mitral regurgitation.
In over-tethering as shown in fig. 3B, the leaflets of a properly configured valve may not function properly due to annular enlargement or shape change (so-called annular enlargement 240). This functional mitral regurgitation is usually caused by myocardial failure and concomitant ventricular enlargement. And excessive volume loading caused by functional mitral regurgitation may itself exacerbate heart failure, ventricular and annular dilation, and thereby worsen mitral regurgitation.
Fig. 4A-4B illustrate the regurgitation BF of blood during systole in functional mitral regurgitation (fig. 4A) and degenerative mitral regurgitation (fig. 4B). The increased size of the annulus in fig. 4A, coupled with increased tethering due to hypertrophy of the ventricle 320 and papillary muscles 330, prevents the anterior leaflet 312 and posterior leaflet 314 from opposing, thereby preventing coaptation. In fig. 4B, the tearing of the chordae tendineae 215 causes the posterior leaflet 344 to prolapse upward into the left atrium, which prevents opposition to the anterior leaflet 342. In either case, the result is regurgitation of blood into the atrium, which reduces the effectiveness of left ventricular compression.
Fig. 5A illustrates an embodiment of a coaptation assistance device 500. The coaptation assistance device 500 can include a coaptation assistance body 515. The coaptation assistance body 515 can include a first coaptation surface 535. The first coaptation surface 535 can be disposed toward the native leaflets of the insufficiency, in the case of the mitral valve, toward the posterior leaflets when implanted. The coaptation assistance body 515 can include a second coaptation surface 540. The second mating surface 540 may be opposite the first mating surface 535, as shown in fig. 5A. The second apposition surface 540 may be disposed toward the native leaflets of the insufficiency, in the case of the mitral valve, toward the anterior leaflets when implanted. The first and second apposition surfaces 535, 540 may be bounded by first and second lateral edges. The first and second apposition surfaces 535, 540 may be bounded by lower and upper edges 545.
The first and second apposition surfaces 535, 540 are two sides of the same implant structure that forms the apposition aid body 515. In some embodiments, the shape of the coaptation assistance body 515 can be generally characterized by the shape of the upper rim 545, the shape of the first coaptation surface 535, and the second coaptation surface 540.
The coaptation assistance device 500 can include a ventricular projection 525, as shown in fig. 5A. The ventricular projection 525 may extend from a lower edge of the coaptation assist body 515. The ventricular projection 525 may be placed within the left ventricle when implanted. The ventricular projection 525 may provide an anchoring mechanism. The distal end 530 of the ventricular projection 525 generally provides an anchoring mechanism.
The distal end 530 of the ventricular projection 525 may have a different shape, as shown in fig. 5C. Fig. 5C shows five embodiments of the distal end 530. It is noted that many more variations are possible and that these variations are not limited to the five embodiments shown in fig. 5C. Generally, and in other embodiments, there are two types of anchors. Examples of passive anchors are shown in fig. 5C in embodiments 555.1-555.4. Passive anchors rely on capture behind the chordae (entrampment) and/or interference with the chordae. With respect to passive anchors, in some embodiments, the maximum dimension or dimension (typically the width) responsible for winding the chordae tendineae may be 10mm-40mm, such as 25 mm.
The distal end 555.1 includes one or more prongs. The prongs may be elongated rods that extend from a central hub as shown. In the illustrated embodiment, four prongs extend from the central hub. In other embodiments, one or more prongs extend from the central hub. The prongs may extend at an angle to the central hub, thereby increasing the surface area of distal end 530. The distal end 555.2 may be generally rectangular, generally square, generally diamond shaped, or diamond shaped. The distal end 555.2 may include one or more cuts (cut out cuts). The incision may increase the ability to grasp tissue. In the illustrated embodiment, four cuts are made in the distal end. In other embodiments, one or more cuts are provided.
The distal end 555.3 includes one or more prongs. The prongs may be elongated rods that extend from a central hub as shown. In the illustrated embodiment, two prongs extend from the central hub. In other embodiments, one or more prongs extend from the central hub. The prongs may extend at right angles to the central hub, thereby increasing the surface area of distal end 530.
The distal end 555.4 includes one or more barbs. The barbs may extend from the central hub as shown. The barb may be inverted toward the central hub. In the illustrated embodiment, three or more barbs extend from the central hub. In other embodiments, one or more barbs are provided in one or more directions.
The distal end 555.5 includes one or more prongs and is similar to the configuration shown as distal end 555.1. Distal end 555.5 is an example of an active anchor. The active anchors may have components such as spikes, barbs, or screws that may be coupled to the ventricular tissue. The active anchor may require a driving force, such as torque, to embed into the tissue. The passive or active anchors may be made of implant grade biocompatible materials such as silicone, PEEK, pebax, polyurethane.
The dimensions of the coaptation assistance device 500 are described in detail in fig. 5D. This figure shows a top view and a front view of the coaptation assistance body 515 of the coaptation assistance device 500. The three parameters "x", "y", and "z" shown in the figures characterize the coaptation assistance device 500. Non-limiting examples of the ranges and sizes of these variables x, y and z are shown in the "size table" in the figures.
The coaptation assistance device 500 can include a support structure 505. The support structure 505 may be referred to as a ridge. The support structure 505 may at least partially define the shape of the coaptation assistance device 500.
Returning to fig. 5A, the support structure 505 is shown by dashed lines. In some embodiments, support structure 505 is made of a shape memory material such as, but not limited to, nitinol (NiTi), Polyetheretherketone (PEEK) or other rigid polymers or fatigue resistant metals. The use of shape memory materials enables the advantages described herein to be achieved. For example, one advantage of the shape memory material is its superelastic properties that help the coaptation assistance device 500 retain its shape and function as a coaptation assistance device when the heart contracts and expands and applies pressure to the coaptation assistance device 500. Another example of an advantage is that shape memory materials are suitable for the transdermal delivery methods to be described herein.
The support structure 505 may comprise one or more segments. In some embodiments, support structure 505 comprises one segment. In some embodiments, support structure 505 comprises two segments. In some embodiments, support structure 505 comprises three or more segments. In some embodiments, one or more segments of the support structure 505 may comprise one or more subsections. In the embodiment shown in fig. 5A, support structure 505 comprises two segments: a first segment 505.2 and a second segment 505.1.
The first segment 505.2 may extend across at least a portion of the coaptation assistance device 500 between the upper edge 545 and the ventricular projection 525. In some embodiments, the first segment 505.2 may extend the entire length of the coaptation assistance device 500 between the upper edge 545 and the ventricular projection 525. In some embodiments, the first segment 505.2 extends from a location between the superior edge 545 and the inferior edge of the coaptation assist body 515. In some embodiments, the first segment 505.2 extends from a location between a lower edge of the coaptation assist body 515 and the ventricular projection 525. In some embodiments, the first segment 505.2 extends along the coaptation assist body 515 and continues to support the ventricular projection 525.
The second segment 505.1 may extend between the first lateral edge and the second lateral edge over at least a portion of the coaptation assist body 515. In some embodiments, the second segment 505.1 may extend the entire length between the first and second side edges. In some embodiments, the second segment 505.1 extends from a location between the superior edge 545 and the inferior edge of the coaptation assist body 515. In some embodiments, the second segment 505.1 extends from a position closer to the upper edge 545 than to the lower edge of the coaptation assist body 515. In some embodiments, the second segment 505.1 extends from the first lateral edge towards the second lateral edge. In some embodiments, the second segment 505.1 extends from the second side edge towards the first side edge. In some embodiments, the second segment 505.1 extends along the segment between the first lateral edge and the second lateral edge. In some embodiments, the second segment 505.1 extends along an edge of the coaptation assistance device 500.
In some embodiments, the first section 505.2 and the second section 505.1 of the support structure 505 may be one integral piece or structure. In some embodiments, the first section 505.2 and the second section 505.1 of the support structure 505 are separate components. In some embodiments, the first segment 505.2 and the second segment 505.1 may be two separate segments that are joined together by methods such as, but not limited to, crimping and laser welding.
In some embodiments, the first segment 505.2 is integrated within the coaptation assist body 515 as described herein. In some embodiments, the first segment 505.2 is integrated within a ventricular projection 525 as described herein. In some embodiments, the first segment 505.2 is removable from the coaptation assist body 515 as described herein. In some embodiments, the first segment 505.2 is removable from the ventricular projection 525 as described herein. In some embodiments, the second segment 505.1 is integrated within the coaptation assist body 515 as described herein. In some embodiments, the second segment 505.1 is removable from the coaptation assist body 515 as described herein. In some embodiments, first segment 505.2 may have a first region oriented substantially parallel to the longitudinal axis of body 515 and a second region oriented substantially perpendicular to the longitudinal axis of body 515, as illustrated.
The support structure 505 that supports the shape of the ventricular projection 525 can have various cross-sections as shown by section AA in fig. 5A and is illustrated in detail in fig. 5B. In fig. 5B, five embodiments of cross-sections are shown; however, it is noted that the embodiments of the cross-section of the support structure 505 are not limited to these five. The cross-section 550.1 is circular or substantially circular. The cross-section 505.2 is circular or substantially circular. Cross-section 550.1 may have a larger cross-sectional area than cross-section 550.2. Cross-section 550.3 includes a plurality of circular or substantially circular cross-sections. In the illustrated embodiment, seven circular or substantially circular cross-sections collectively form cross-section 550.3. In other embodiments, two or more circular or substantially circular cross-sections collectively form cross-section 550.3. Cross section 550.3 may be in the form of a cable. The cross-section 550.4 is rectangular or substantially rectangular. The cross-section 550, 5 is rectangular or substantially rectangular. Cross-section 550.4 may have a larger cross-sectional area than cross-section 550.5.
It is further noted that the first section 505.2 and the second section 505.1 may also have different cross-sections. Each cross-section or embodiment shown in fig. 5B may have certain advantages, such as some cross-sections may be easily bendable in one direction and not easily bendable in another direction. Some other cross-sections may have higher reliability characteristics than others. The characteristics of each type of cross-section, as well as the range and non-limiting possible dimensions of the cross-sections in table 2 in fig. 5E, are described for two different materials, nitinol and PEEK. Although a variety of configurations are presented in table 2, in some embodiments, both cross-sections 550.4 and 550.5 may be utilized for both materials.
When the coaptation assistance device 500 is placed within the heart, in some embodiments, the coaptation assistance device 500 is such that the ventricular projection 525 will be substantially placed within the left ventricle, as shown in fig. 5G. The ventricular projection 525 provides a mechanism for anchoring the coaptation assistance device 500 using the structure of the ventricle. An example of positioning the coaptation assistance device 500 over the posterior leaflet is illustrated in fig. 5G.
Keeping in mind that other examples of positioning are possible and discussed elsewhere within this disclosure, in this particular embodiment, a coaptation assistance device 500 is illustrated having a curvilinear shaped ventricular projection 525. The ventricular projection 525 and/or the first support 505.2 may be constructed of a shape memory material, in which case the curvilinear shape is maintained after implantation. The curvilinear shape may enable the coaptation assistance device 500 to remain in place after coaptation with the native valve leaflets 14.
Fig. 5F shows an embodiment of a passive anchor for a ventricular projection 525. In this embodiment, the tube 560 running along the length of the ventricular projection 525 terminates at two tubes 565.1 and 565.2 at the distal end of the coaptation assistance device 500. The coaptation assistance device 500 can be delivered to the left side of the heart with the straightened wire such that the two tubes 565.1 and 565.2 are approximately straight, as shown by the dashed lines 565.1 and 565.2 (position a), indicating that the straightened wire is in an advanced state. In some embodiments, the two tubes 565.1 and 565.2 may be made of a shape memory material including, but not limited to, polyurethane, silicone, polyethylene, pebax, and nylon. Without the straightened wire, the two tubes 565.1 and 565.2 may have a default shape that may be coiled or coiled, as shown by solid lines 565.1 and 565.2 in fig. 5F (position B).
After the implant is properly delivered and placed in the heart, the straightened wire can be withdrawn, allowing the two tubes 565.1 and 565.2 to assume their default shape (position B). The two tubes 565.1 and 565.2 may provide anchoring support due to the entanglement with the chordae tendineae. An advantage of this type of anchoring is that if it becomes necessary to reposition the coaptation assistance device 500 due to unsatisfactory placement, the straightened wire can be advanced back into the two tubes 565.1 and 565.2, aligning the two tubes 565.1 and 565.2 and causing the two tubes 565.1 and 565.2 to disengage from the chordae structure. While the above-described embodiment describes two tubes 565.1 and 565.2, it is understood that one, two, or more tubes may be present.
Yet another embodiment of an anchor coaptation assistance device 500 is illustrated in fig. 5H. The active anchor may be coupled to the distal end of the ventricular projection 525. After delivery of the implant, the active anchors may be driven through the posterior leaflet to couple to the coaptation assistance device 500 at the annulus (atrial) level as shown. Methods of positioning and driving the anchors will be discussed herein.
In another embodiment, the tip of the ventricular projection 525 can be radiopaque or echogenic to aid in the placement and anchoring of the coaptation assistance device 500 when the coaptation assistance device 500 is percutaneously placed. In such procedures, a fluorescence or ultrasound imaging modality may be used to visualize the heart and the coaptation assistance device 500.
Returning to fig. 5A, in another embodiment, the coaptation assistance device 500 can include a hub (hub) 510. The hub 510 may have one or more purposes. One purpose may be to act as an anchoring device as discussed herein. Another purpose may be to provide a mechanism for percutaneously delivering the coaptation assistance device 500 as discussed herein. In some embodiments, a hub (not shown) may be present at the distal end of the coaptation assistance device 500. The hub may be located at the end of the ventricular projection 525. The ventricular hub may be located at the distal-most tip of the distal end 530 of the ventricular projection 525. To distinguish the two hubs, the hub 510 on the proximal side will simply be referred to as the "hub," annulus hub, "or" proximal hub. The hub at the distal tip of the ventricular projection will be particularly referred to as the "ventricular hub".
Referring also to fig. 5A, the coaptation assistance body 515 of the coaptation assistance device 500 can be made from a variety of biocompatible materials, such as expanded polytetrafluoroethylene (ePTFE). This material provides a coaptation surface against which the anterior leaflet will close. The coaptation assistance body 515 of the coaptation assistance device 500 can be coupled to the support structure 505 such that the shape of the support structure 505 imparts the general shape of the coaptation assistance device 500.
The shape of the coaptation assistance device 500 can be further supported by one or more ribs 546 (not shown). One, two, or more ribs 546 may be present. The ribs 546 may be made of a variety of materials such as, but not limited to, sutures, polypropylene, nylon, NiTi cable, NiTi wire, and PEEK. A process of coupling the coaptation assistance body 515 of the coaptation assistance device 500 to the support structure 505 and/or the ribs 546 (if the ribs 546 are present) is described herein.
In some manufacturing methods, the process may begin by sliding a Polyethylene (PE) tube over support structure 505 and/or ribs 546 (if ribs 546 are present). The combination is placed between two ePTFE sheets, after which heat and pressure are applied. The ePTFE is bonded to the PE tube due to the small pores in the ePTFE material, and the polyethylene material of the tube can melt into the small pores in the ePTFE material to form a mechanical bond. Similarly, the PE tube material may melt into the micro-holes in the support structure 505 and/or the ribs 546 when heat and compression are applied. Micro-holes in the support structure 505 and/or the ribs 546 may be carefully placed to improve adhesion.
In a variation of the above process, a PE sheet may be placed, in which case there may be no PE tube present. In this variation, as described above, a simple process of heating and compressing is applied, and a more uniform composite structure can be produced. In further embodiments, the support structure 505 and/or the ribs 546 may have features such as micro-holes that couple to the ePTFE membrane. The fine hole diameter may be, for example, in the range of 0.005 '-0.030'.
In variations on the types of materials that may be used to make the coaptation assistance body 515 of the coaptation assistance device 500, other materials may be utilized such as, but not limited to, sponge material, polyurethane, silicone, bovine or porcine pericardium. Bonding processes may include, but are not limited to, thermal bonding, sewing, and gluing.
With continued reference to fig. 5A, in some embodiments, the coaptation assistance device 500 has perforations or slots 520. One or more such perforations or slots 520 may be present. These perforations 520 may serve the purpose of providing a site where anchors may be placed, as discussed herein.
One advantage of the coaptation assistance device 500 is that the coaptation assistance device 500 can be folded into a smaller configuration. The coaptation assistance device 500 can be delivered percutaneously via a delivery catheter. In some embodiments, support structure 505 is made of a shape memory material. When the coaptation assistance device 500 is deployed within the heart, the desired shape of the coaptation assistance device 500 is regained. A number of embodiments now describe various methods, devices, and systems for delivering the coaptation assistance device 500 into the heart.
In some methods of use, the first support has a first configuration in which the first support 505.2 is substantially linear, and a second configuration in which the first support 505.2 is curved. In some methods of use, the first support 505.2 and the second support 505.1 are configured to allow percutaneous insertion of the coaptation assistance device 500.
The first few steps in the delivery operation may be similar to those known in the art. For example, the patient's body is punctured in the lower torso/upper thigh region (groin) to gain access to the femoral vein. Typically, a trans-septal sheath (trans-septal sheath) and needle are inserted into the inferior vena cava and advanced up to the interatrial septum, at which point a trans-ventricular septal puncture is made, and the trans-septal sheath is advanced into the left atrium. The needle is removed and the transseptal sheath now provides access to the left atrium. More details about the above steps can be found in the public medical literature.
The method may include various steps including those now described. The ventricular projection 525 of the coaptation assistance device 500 can be placed substantially within the left ventricle. Various guidance techniques may be advantageously used to guide the coaptation assistance device 500 to this position. For example, a simple guidewire may be placed within the transseptal sheath and guided into the left ventricle by first entering the left atrium and passing through the mitral valve. However, a simple guide wire may not provide sufficient accuracy in placement of the ventricular projection 525.
In some embodiments, methods of placing a guide wire within a steerable sheath can be used. The steerable sheath with the guide wire can be advanced across the septal sheath and then through the mitral valve into the left ventricle where the steering capability of the steerable sheath will provide additional support for properly positioning the guide wire. After placement of the guide wire, the steerable sheath needs to be removed prior to delivery of the coaptation assistance device. This method, while providing more accurate positioning of the guide wire, involves an additional step of removing the steerable sheath. To improve this process in terms of reducing the number of steps required to perform the implantation, various embodiments of steerable sheaths are disclosed herein.
Small diameter steerable catheter
Referring to fig. 6A, a small diameter steerable catheter 600 is illustrated. In some embodiments, the diameter 615 of the handle 610 of the steerable catheter 600 can be equal or substantially equal to the diameter 620 of the body 605 of the steerable catheter 600. A pull wire 625 may be provided within steerable catheter 600. When handle 610 is rotated, for example in the direction of arrow 632, the distal portion of steerable catheter 600 is moved from straight position 630 to curved position 640 along arrow 635. The curved position 640 may be beneficial for positioning the ventricular projection 625, as discussed herein. When the handle 610 is rotated, such as in the opposite direction of arrow 632, the distal portion of the steerable catheter 600 moves along the curved position 640 to the straight position 630. The linear position 630 of steerable catheter 600 is shown in phantom, not to be confused with pull wire 625, which is also shown in phantom. The linear position 630 may be beneficial for anatomically inserting or withdrawing the steerable catheter 600.
In some embodiments, the diameter of the handle 610 may be equal to the diameter of the body 605. This may be advantageous because the coaptation assistance device 500 can be slid through the handle 610 and/or the body 605 after the steerable catheter 600 is placed in the ventricle. In some embodiments, steerable catheter 600 can include an extension body 612 at a proximal end extending from handle 610. The extension 612 may be a wire or other elongated structure. The purpose of extension body 612 is to assist in loading other catheters or devices while allowing a clinician or other operator to maintain control of steerable catheter 600. After loading other catheters or devices onto extension body 612, other catheters or devices are guided using steerable catheter 600. The length of extension body 612 may match or exceed the length of the catheter or device being loaded such that control of steerable catheter 600 is maintained during loading and delivery of other catheters or devices.
In some embodiments, the extension 612 may be coupled to the handle 610 only when necessary. For example, if during operation, a medical team decides that a longer catheter is necessary, an extension body 612 may be coupled to the handle 610. The coupling mechanism may include, but is not limited to, a threaded connection, a press fit, or other mechanism.
Non-limiting examples of the dimensions of the various sub-components (body 605, handle 615, extension 612) in some embodiments may be as follows: the diameter 620 of the body 605 may range from 2 to 10Fr, such as 4Fr, from about 2Fr to about 6Fr, from about 3Fr to about 5Fr, or less than 10Fr, 9Fr, 8Fr, 7Fr, 6Fr, 5Fr, 4Fr, 3Fr, or 2 Fr. The handle 610 may in some cases be about 1/2 "to about 2", such as about 1 ", in length, and the range of linear handle travel (for activating the pull wire) may in some cases be about 1/8" to about 3 ", such as about 1/4".
During the implantation procedure, some methods involve a guide wire or guide wire and a steerable sheath. In some methods, steerable catheter 600 may be advanced through a femoral approach. Since the handle 610 is outside of the patient's body, it can be rotated so that the distal portion of this steerable catheter 600 is placed in position under the posterior leaflet. An extension 612 may be attached to the proximal end of the handle 610, allowing for subsequent loading of the coaptation assistance device 500 and the delivery catheter 700 prior to insertion into the transseptal sheath 650, as described herein. This delivery catheter 700 may then be used as a guide for introducing the coaptation assistance device 500, as will be explained herein.
Fig. 6B illustrates placement of steerable catheter 600 in the heart. An embodiment of a cross-septal sheath 650 is shown. Also shown are left atrium 655, left ventricle 660, posterior leaflet 665 of the mitral valve, and anterior leaflet 670 of the mitral valve. The steerable catheter 600 is shown passing through the mitral valve and positioned under the posterior leaflet 665. It can now be appreciated how having the ability to deflect the distal portion of the steerable catheter 600 can be advantageous so that a suitable location of the coaptation assistance device 500 can be obtained. The distal portion of the steerable catheter 600 can be bent under the posterior leaflet 665 as shown. In some methods, the next general step after placement of the steerable catheter 600 is to deliver the coaptation assistance device 500 to the heart. Further embodiments are now described with respect to methods and apparatus for effecting delivery.
Delivery catheter
Referring to fig. 7A, a delivery catheter 700 is now described. The function of the delivery catheter 700 is to carry the coaptation assistance device 500 to the heart. Shaft 710 of delivery catheter 700 may be torqueable and deflectable. The shaft 710 is shown cross-hatched. The delivery catheter 700 may include a handle 730. The handle 730 may have a rotation mechanism, such as a pull wire or the like. The rotation mechanism may deflect and steer the shaft 710. Distal to the handle 730 is an implant sheath 725, which may carry the coaptation assistance device 500 to the heart, as explained herein. In some embodiments, and even more distal of the implant sheath 725 is a tear away funnel (tear away funnel) 720. The tear-off funnel 720 can facilitate folding of the coaptation assistance device 500. In some embodiments, the distal-most end of the shaft 710 has features that can lock the shaft 710 to the coaptation assistance device 500 so that the coaptation assistance device 500 can be transported to the heart and properly placed. The locking process and components are now described with respect to fig. 7B, 7C, and 7D.
Referring to fig. 7D, the delivery catheter 700 and coaptation assistance device 500 can have mating features (matching features) that enable them to be temporarily locked. In some embodiments, the delivery catheter 700 includes one or more distal locking tabs 705. The coaptation assistance device 500 can include an annulus hub 510 as described herein. The distal locking tab 705 of the delivery catheter 700 may be coupled with a component in the annulus hub 510 of the coaptation assistance device 500, as will be explained herein.
In some methods, the steerable catheter 600 or other guide wire or catheter may be advanced through the ventricular projection 525 and/or the anchoring mechanism 530. In some embodiments, anchoring mechanism 530 may have a hole or passage in the center to allow steerable catheter 600 to pass through, as shown in fig. 7D. Steerable catheter 600 may be passed from anchoring mechanism 530 to annulus hub 510. Other paths through the coaptation assistance device 500 are contemplated. The steerable catheter 600 may be passed from the anchoring mechanism 530 to the annulus hub 510 and further to the delivery catheter 700.
Referring to fig. 7B, the tip of the delivery catheter 700 is shown in an enlarged view. The annulus hub 510 of the coaptation assistance device 500 is also shown. The distal locking tab 705 may be made of some shape memory material such as nitinol. The natural position of the locking tabs 705 is such that they bend inwardly and towards each other as shown in fig. 7A. In some methods, a guide wire or catheter, such as steerable catheter 600, may be inserted into the annulus hub 510 and between the distal locking tabs 705, and the distal locking tabs 705 may be pushed out against the annulus hub 510. The annulus hub 510 is designed with mating slots 740 such that the distal locking tabs 705 fit into these slots 740. As long as the steerable catheter 600 is present to force the distal locking tab 705 outward into the slot 740, the tip of the delivery catheter 700 remains locked to the annulus hub 510. Other locking mechanisms are possible and one such alternative is now described in fig. 7C.
Referring to fig. 7C, the annulus hub 510 may include a plug 745. The pin 745 may be a solid piece that passes through the annulus hub 510 and is held in place by methods known in the art. The delivery catheter 700 may include a loop of wire or suture 750. The suture 750 may be looped around an object, such as a guidewire within the annulus hub 510 or the steerable catheter 600. The suture 750 may extend into the handle 730 of the delivery catheter 700. Handle 730 may have a mechanism to control the tension of suture 750. By controlling the tension, the coaptation assistance device 500 can be pulled against and can be securely fixed to the distal end of the delivery catheter 700. When steerable catheter 600 is withdrawn past the level of the cross-pin 745, loop 755 of suture 750 may slide over the cross-pin 745, thereby releasing the cross-pin 745 and coaptation assistance device 500.
Delivery procedure
Fig. 8A-8D show the delivery method. In some methods, the implant sheath 725 and the funnel 720 are advanced over the coaptation assistance device 500. The implant sheath 725 and the funnel 720 can be advanced over the coaptation assistance device 500 after the delivery catheter 700 is locked with the coaptation assistance device 500. The shape of the funnel 720 assists the coaptation assistance device 500 in closing or folding over on itself. Advancement of the implant sheath 725 and the funnel 720 is shown in fig. 8A and 8B. Arrow 760 in fig. 8A indicates how the coaptation assistance device 500 is pulled into the funnel 720. Once the coaptation assistance device 500 is within the implant sheath 725, the funnel 720 is removed. In some embodiments, the funnel 720 is removed by pulling on the tab 715, thereby rupturing the funnel 720, shown in fig. 8C. The funnel 720 and tab 715 may then be discarded. In some methods, an implant sheath 725 containing the coaptation assistance device 500 can be advanced over a guidewire or steerable catheter 600. It is reiterated that the advantages of the design of the steerable catheter 600 become apparent when the coaptation assistance device 500 can slide smoothly over the steerable catheter without any difficulty due to the different sized diameters of the handle 610 and the body 605. The implant sheath 725 may be inserted into the transseptal sheath 650 as shown in fig. 8D.
The system of the coaptation assistance device 500 and the implant sheath 725 is advanced until it exits the crossing spacer sheath 650, as shown in fig. 8E. The delivery catheter 700 is deflected such that the implant sheath 725 is positioned between the leaflets of the mitral valve, which is shown in fig. 8E. The implant sheath 725 is placed between the chordae tendineae 765 (the "P2" position). Once the implant sheath 725 reaches this location, the delivery catheter 700 is held in place and the implant sheath 725 is slowly withdrawn, causing the coaptation assistance device 500 to begin to exit the implant sheath 725, as shown in fig. 8F. Note that the steerable catheter 600 or equivalent guidewire is still just below the posterior leaflet and can still be actively adjusted or deflected using the control handle 610. In some methods, as the delivery catheter 700 is advanced, the coaptation assistance device 500 is advanced out, following the path of the steerable catheter 600 until the distal end 530 of the ventricular projection 525 couples to the ventricular tissue. This is illustrated in fig. 8G. The implant sheath 725 may be withdrawn while the coaptation assistance device 500 is being advanced. In some methods, rotational adjustment of the delivery catheter 700 may be made to ensure proper placement.
Anchoring
Once the coaptation assistance device 500 is opened, the method can include anchoring the coaptation assistance device 500 in an atrial aspect of the mitral valve, i.e., on the mitral annulus. Several embodiments now describe methods and systems for implementing anchoring.
A support structure 505 made of a shape memory material may be advantageous. The shape assumed by the coaptation assistance device 500 is intended to result from the action of the shape memory material when the coaptation assistance device 500 is opened. As described herein, the shape of the coaptation assistance device 500 can be intended to provide a new coaptation surface such that regurgitant flow is reduced or eliminated. Returning to the explanation of the delivery and anchoring process, the delivery catheter 700 (which may still be coupled to the annular hub 510 of the coaptation assistance device 500) can now be manipulated (both rotationally and axially) to properly position the coaptation assistance device 500 over the posterior leaflet of the native leaflet. In an embodiment, the support structure 505 of the coaptation assistance device 500 can have a component that can be attached to tissue. In some embodiments, the components are passive hooks. In some methods, these components engage the annulus so that the coaptation assistance device 500 can be held in place while anchoring is initiated. Fig. 8H shows the condition of the delivery catheter 700 with the implant sheath 725 withdrawn and the shaft 710 still coupled to the annulus hub 510.
An embodiment of the anchor 800 is illustrated in detail in fig. 8I. The anchor 800 can be coupled to the delivery catheter 700 and/or the coaptation assistance device 500 in a variety of ways. The annulus hub 510 may have a pin 512. The pin 512 may provide a location around which the helical structure 815 of the anchor 800 may be wrapped, as shown. Anchor 800 may have a shoulder 805. The shoulder 805 may fit snugly against the shaft 710 of the delivery catheter 700. The shoulder 805 may have features, such as windows 810, that may lock the distal locking tabs 705 of the delivery catheter 700. The distal locking tab 705 of the delivery catheter 700 may lock when a pin, guidewire, or catheter, such as the steerable catheter 600, is present within the shaft 710 of the delivery catheter 700. In some methods, the anchor 800 may be pre-loaded onto the coaptation assistance device 500 and locked in place with the delivery catheter 700 during the process of installing the coaptation assistance device 500 onto the delivery catheter 700. This may occur before the coaptation assistance device 500 is pulled into the implant sheath 725 and is ready for insertion into the femoral vein. Returning to fig. 8H, torque can be applied to the shaft 710 such that the anchor 800 is driven into the tissue. To provide feedback as to whether the anchor 800 is properly secured, a fluorescent marker may be present on the anchor 800. The marker may be located at the proximal end. These markings may inform the medical team about how far the anchor 800 may travel toward the annulus hub 510 and may inform about when the anchor 800 is securely fixed in place. In some embodiments, to ensure that the proper torque is applied, the torque level at the handle 730 may reach a peak (spike) when the anchor 800 bottoms out on the annulus hub 510. This increased torque level may be felt at the handle 730, providing feedback that the appropriate torque has been applied. The central guide wire or steerable catheter 600 can be withdrawn. This causes the distal locking tab 705 to retract from the window 810 of the anchor 800, thereby unlocking the delivery catheter 700 and anchor 800. This may result in the release of the coaptation assistance device 500. Delivery catheter 700 and steerable catheter 600 can now be completely withdrawn.
Commissural anchoring
Several embodiments illustrate commissure anchors. One such embodiment is shown in fig. 9A. The delivery catheter 700 (not shown) has been withdrawn and the anchor catheter 900 has been advanced through the femoral approach. The anchor catheter 900 is torqueable. One or more anchoring catheters 900 may be provided. The distal tip of the anchor catheter 900 may have one or more features to lock the anchor in place during delivery of the anchor. In fig. 9A, the distal tip has a cut 905 that can receive a portion of the helical anchor 915. The anchoring catheter 900 may also have a central pin 920. The central pin 920 may have a pointed tip on the distal tip. In some embodiments, the central pin 920 may have the ability to be withdrawn.
Fig. 9A shows a ring 910. The end (not shown) of the loop 910 may travel to the handle of the anchoring catheter 910 or a portion of the length therebetween so that the tension of the loop 910 may be controlled. The loop 910 is coiled past a cross-bar 917 or other portion that forms the proximal portion of the helical anchor 915. A top view of the helical anchor 915 with cross-bar 917 is shown in fig. 9B. When outside the body, the helical anchor 915 may be placed adjacent the central pin 920 prior to entering a trans-septal sheath (not shown). The loop 910 may be arranged in such a way that when tension is applied to the loop 910, the loop 910 holds the screw anchor 915, and the central pin 920, locked in place. In fig. 9A, this arrangement is collapsed such that the cut 905 receives the proximal portion of the helical anchor 915. The retaining ring 910 is in tension, advancing the entire structure into the transseptal sheath.
Once in the desired location within the body, the anchor catheter 900 is adjusted so that the distal end of the anchor catheter 900 is positioned over the commissure holes 520. The central pin 920 and the helical anchor 915 are advanced such that the central pin 920 first pierces the tissue after passing through the engagement hole 520. Torque is applied to the anchoring catheter 900 and the helical anchor 915 pierces the tissue. The helical anchor 915 anchors the support structure 505 or the frame of the coaptation assistance device 500 to tissue. After the helical anchor 915 is in place, the central pin 920 is withdrawn. Withdrawal of the central pin 920 may allow the loop 910 to slide over the crossbar 917 of the helical anchor 915, thereby releasing the anchor 915. This process can be used repeatedly with other commissure sites to anchor the two end protrusions of the coaptation assistance device 500.
Alternative anchoring techniques
Fig. 10A shows an alternative anchoring technique in another embodiment. In this embodiment, the delivery catheter 1000 may have multiple lumens 1040. The delivery catheter 1000 may have a cross-section as shown in fig. 10B. The inner lumen 1040 may carry a single distinct twistable drive shaft. Each drive shaft may be locked to an anchor (as in the case of shafts 1020 and 1030) or to the annulus hub 510 (as shown for shaft 1010). Each of the twistable shafts 1010, 1020, 1030 may have the design of the anchor catheter 900 illustrated in fig. 9A. The delivery catheter 1000 may have a central lumen 1050, and the guidewire or steerable catheter 600 may pass through the central lumen 1050. The plurality of twistable drive shafts 1010, 1020, 1030, the guide wire or steerable catheter 600, and the coaptation assistance device 500 can all be loaded into and withdrawn from the implant sheath of the delivery catheter 1000 prior to entering the trans-septal sheath. Such that the entire arrangement can be advanced and the same procedure as explained herein can be followed to place the coaptation assistance device 500. An advantageous aspect of this arrangement is that the anchoring process can be accomplished without the need to withdraw the anchoring catheter, reload the anchor and re-enter the body multiple times.
Alternative design for anchor
Although a few anchors have been described herein, other alternative embodiments are contemplated. Fig. 11A shows an anchor with a claw hook. Fig. 11B shows an anchor resembling an umbrella. In both embodiments, the anchor may be made of a shape memory material. In both embodiments, the anchor can be loaded into a delivery catheter (such as the delivery catheter illustrated in fig. 11C).
A locking mechanism, such as those described herein, may be used to lock the anchor to the delivery catheter. The delivery catheter may have a pointed tip so that the delivery catheter can be guided to a suitable location and initially pierce tissue. After the delivery catheter is placed in the appropriate location and the initial puncture is made, one or more anchors may be advanced and installed in place. This step is followed by unlocking and withdrawing the delivery catheter.
Fig. 11D is an illustration of how the umbrella anchor of fig. 11B looks after it has been installed into tissue to anchor the coaptation assistance device 500. Due to the natural unstressed shape of the anchor, when deployed in tissue on the coaptation assistance device 500, the deformed shape will have an effective spring force against the face of the coaptation assistance device 500, ensuring a good footing.
Ridge-free implant
The coaptation assistance device 500 depicted in fig. 5A-F can include a support structure 505. The support structure 506 may be made of a shape memory material as described herein. In some embodiments of the coaptation assistance device, another configuration is contemplated. This configuration may be referred to as an invertebrate coaptation assistance device to indicate removal of the support structure after placement of the coaptation assistance device in the heart. Both types of coaptation assistance devices may have certain advantages. The ridgeless coaptation assistance device may be advantageous because of fewer components and materials and the absence of metal fatigue.
Fig. 12 shows an embodiment of an invertebrate coaptation assistance device 1200. The spinal-free coaptation assistance device 1200 can include a tube or passageway 1210. The passage 1210 may be placed around the edge of the annulus. This passage 1210 may be referred to as a valve collar. The spinal-less coaptation assistance device 1200 can include a tube or passageway 1212 along the ventricular projection. This passageway 1212 may be referred to as a ventricular tube.
The cross-section of the passage 1210 can be shown towards the end of the valve collar. Although a circular cross-section is illustrated, the tubes or passageways 1210, 1212 may have other cross-sections including, but not limited to, oval and flat.
The support structures 1210.1, 1210.2, 1210.3 are shown by dashed lines, except at the edge of the annulus where the support structures 1210.1 and 1210.3 protrude. The support structure 1210.1, 1210.2, 1210.3 may have three different segments, with 1210.1 and 1210.3 placed in the valve annulus tube and 1210.2 placed in the ventricular tube. The support structures 1210.1, 1210.2, 1210.3 may be coupled within a ridged pivot 1220. In some embodiments, the support structures 1210.1, 1210.2, 1210.3 may be different and separate segments. In some embodiments, the support structures 1210.1, 1210.2, 1210.3 may be joined together using one of a variety of methods, such as, but not limited to, crimping and laser welding. This arrangement of the support structures 1210.1, 1210.2, 1210.3 and the coaptation assistance device 1200 allows the support structures 1210.1, 1210.2, 1210.3 to be withdrawn from the coaptation assistance device 1200. In some methods, the support structures 1210.1, 1210.2, 1210.3 are extracted by applying a pulling force to the ridged pivot 1220. More details regarding the coaptation assistance device 1200 and the procedures for delivering and anchoring the coaptation assistance device 1200 will be provided herein.
Ridge-free implant delivery procedure
Fig. 13A and 13B illustrate a delivery procedure of the coaptation assistance device 1200. Fig. 13A shows the coaptation assistance device 1200 of fig. 12. Fig. 13A shows an additional component, an anchoring site 1300. This anchoring location 1300 will be described in greater detail herein.
The steerable catheter 600 can be inserted into the coaptation assistance device 1200. The steerable catheter 600 may be inserted from the distal tip of the ventricular projection 1212. Steerable catheter 600 may exit from exit aperture 1335. A delivery catheter 1320 may be provided. The delivery catheter 1320 may include a torqueable shaft 1310. The delivery catheter 1320 can include a hub locking feature 1330 coupled to the hub anchor 1300. In fig. 13A, the hub locking member 1330 is shown as a screw. Other locking mechanisms as explained herein may be utilized.
Fig. 13B illustrates more detail with respect to the delivery catheter 1320. The distal tip of the delivery catheter 1320 may include a funnel 1360. Proximal to the funnel 1360, an implant introducer 1340 may be present. At the proximal-most end, the delivery catheter 1320 may have a handle 1370.
The steerable catheter 600 can be passed through a coaptation assistance device 1200 as described herein. The funnel 1360 may be inserted over the distal tip of the delivery catheter 1320. The coaptation assistance device 1200 can be locked in place using the locking member 1330 such that the hub anchor 1300 is connected to the twistable shaft 1310.
The steerable catheter 600 can be passed through an angled side port 1350 on the implant introducer 1340. The coaptation assistance device 1200 and the steerable catheter 600 can be pulled through the funnel 1360 by withdrawing the delivery catheter 1320. With continued withdrawal, the coaptation assistance device 1200 folds upon itself within the implant introducer 1340. Once the implant is in the introducer 1340, the funnel 1360 is removed and discarded. The funnel 1360 may be designed such that it may be easily removed. Designs for the funnel include, but are not limited to, a tear-away design (previously shown in fig. 8A-8C) or a clamshell design (fig. 13B).
The delivery catheter 1320, along with the implant introducer 1340, can be advanced over the steerable catheter 600 until the implant introducer 1340 couples with the hub of the crossing sheath 650. At this point, the implant introducer 1340 may not be able to advance further, and the coaptation assistance device 1200 itself may advance into the transseptal sheath. The next several steps are similar to those shown in fig. 8E-8G, except that in this embodiment, an implant sheath is not used. The coaptation assistance device 1200 is placed over the posterior leaflet and the ventricular projection 1212 is placed in the left ventricle. Steerable catheter 600 may be withdrawn such that ventricular projection 1212 is crimped or coiled under P2. Once the ventricular projection 1212 is anchored, the hub anchor 1300 may be rotated or otherwise actuated. The hub anchor 1300 may anchor the proximal side of the coaptation assistance device 1200 to the annulus. The twistable shaft 1310 may be withdrawn. After additional anchoring (as will be explained herein), the hub locking member 1330 is withdrawn, pulling the support structure 1210.1, 1210.2, 1210.3 with it. The coaptation assistance device 1200 can now be operated in the left heart without the support structures 1210.1, 1210.2, 1210.3.
Anchoring procedure for a spinal-free implant
Fig. 14A shows an embodiment for anchoring a coaptation assistance device 1200. Since rigid structures such as support structures 1210.1, 1210.2, 1210.3 may not be present after implantation, additional anchors may be required for the coaptation assistance device 1200. In some embodiments, the coaptation assistance device 1200 can utilize closely packed anchors. In some embodiments, the coaptation assistance device 1200 can utilize additional closely packed anchors in addition to similar coaptation assistance devices having a support structure 505 described herein. Fig. 14A shows an embodiment of an anchor 1400 that can be used to couple a coaptation assistance device 1200 to tissue. Fig. 14B shows another embodiment. In fig. 14B, a suture or tape 1410 is used to "suture" the coaptation assistance device 1200 to tissue. The suture or tape 1410 may be made of one of several materials including, but not limited to, polypropylene or nylon. Several embodiments describing how to place multiple anchors are now explained herein.
Fig. 15A shows an embodiment of an anchor catheter 1500 that delivers multiple anchors. Several anchors 1510 (including anchor 1510.1 and anchor 1510.2) are stacked within the anchor catheter 1500. Although fig. 15A shows two anchors 1510.1 and 1510.2 stacked within the anchor catheter 1500, more or fewer anchors may be stacked. Each anchor 1510 may include a coiled section 1550. The coiled section 1550 may include a prong 1570. The anchor 1510 can include an anchor head 1560. The anchor head 1560 may have one of several cross-sections as shown by 1545.1, 1545.2, 1545.3 and 1545.4 in fig. 15A. Other cross-sections are possible.
To initially load the anchor catheter 1500, the anchors 1510 are loaded onto the central shaft 1520 of the anchor catheter 1500. The central shaft 1520 and the anchor 1510 may have matching cross-sections such that the anchor 1510 may be rotationally coupled to the central shaft 1520. At the proximal end of the anchor catheter 1500, a spring 1540 may be included. This spring 1540 provides a pushing force that causes the central shaft 1520 to rotate and the anchor 1510 exits the distal end of the anchor catheter 1500 in the direction of arrow 1550. When the anchors 1510 are withdrawn, the anchors 1510 can engage the coaptation assistance device 1200 and the tissue to couple the coaptation assistance device 1200 to the tissue. Rotation of the central shaft 1520 may be controlled by an operator, such as a physician. In some embodiments, the central shaft 1520 is coupled to a torqueable wire (not shown), which may be coupled at a proximal end to a handle (not shown). In some embodiments, the wire to which torque may be applied may be manually controlled. In some embodiments, the wire to which torque may be applied may be controlled via a motor. Methods for imparting rotational motion to the central shaft 1520 are contemplated. A feature not shown in fig. 15A is the ability to steer and position the distal end of the anchor catheter 1500. When delivering one anchor 1510, the distal tip may need to be repositioned to deliver the next anchor 1510. A steering mechanism such as a pull wire may be included to steer the distal tip of the anchor catheter 1500.
Fig. 15B shows another embodiment of an anchor catheter 1600 that delivers multiple anchors. Fig. 15B shows only the distal tip of the anchor catheter 1600. The anchor catheter 1600 may include a plurality of anchors 1610 such as 1610.1 and 1610.2. Although the anchor catheter 1600 shows five anchors. More or fewer anchors 1610 may be loaded at any one time. The anchor catheter 1600 may have a central shaft 1630. The anchor catheter 1600 may include threads, such as 1620 on the interior of the housing 1605. As shown, these threads 1620 can accommodate the coils of the anchor 1610. To initially load the anchor catheter 1600, the anchor 1610 is inserted into the housing 1605. The anchor 1610 is inserted onto the central shaft 1630. As previously described, the cross-section of the central shaft 1630 may match the cross-section of the anchors 1610 so that the anchors 1610 may be mounted to the central shaft 1630. Rotation of the central shaft 1630 may be controlled by a torque-applicable cable (not shown) that may couple the central shaft 1630 to the handle (not shown) of the anchor catheter 1600. The operator, such as a doctor, can control the rotation. In some embodiments, the wire to which torque may be applied may be manually controlled.
In some embodiments, the wire to which torque may be applied may be controlled via a motor. As the central shaft 1630 is rotated, the threads will force the anchor 1610 out of the anchor catheter 1600 and engage the coaptation assistance device 1200 and tissue to couple the coaptation assistance device 1200 and tissue together. The anchor catheter 1600 can also have a pull wire to steer the distal tip of the anchor catheter 1600 such that when one anchor 1610 is delivered, the anchor catheter 1600 can be positioned to deliver the next anchor 1610.
Fig. 15B illustrates a central suture 1635. The central suture 1635 may include a ball 1640 that is coupled to an end of the central suture 1635. Fig. 15C and 15D illustrate how the central suture 1635 and ball 1640 may be used. The ball 1640 may be seated in a slot in the first anchor 1610.1. The central suture 1635 may connect the first anchor 1610.1 to the second anchor 1610.2 and other anchors 1610 (not shown in the figures). This arrangement can provide the ability to use the central suture 1635 as a guide wire to retract the anchor 1610 after the anchor 1610 has been threaded into the tissue 1645. The operator may wish to retract the anchor 1610 to reposition or adjust the anchor 1610. Additionally, if one or more anchors 1610 become loose, the central suture 1635 may provide a tether for the loose anchor 1610, thus preventing embolic events.
Fig. 16A-C show another embodiment of an anchoring catheter 1700 that delivers multiple anchors. The anchor catheter 1700 may have a hollow shaft. The hollow shaft may be tapered at the distal end, which may be used to pierce the coaptation assistance device 1200 and tissue. A plurality of anchors 1710, such as 1710.1, 1710.2, may be disposed within the hollow shaft of the anchor catheter 1700. Anchor 1710 may be a hollow barrel.
The suture 1720 can be threaded through the anchor 1710 as shown. The suture 1720 may be secured to the first anchor 1710.1 by arranging the suture 1720 to exit the second anchor 1710.2 and enter the first anchor 1710.1 through the side hole 1740. The suture 1720 may then be secured within the first anchor 1710.1 by way of a knot (depicted in phantom). In addition to the first anchor 1710.1, the suture 1720 in other anchors 1710 may appear as shown for anchor 1710.2. A portion of the wall of anchor 1710 other than first anchor 1710.1 is cored out as a cutout. The cut-outs may assist in better embedding the anchor within the tissue, similar to a toggle bolt. At the proximal end of the anchoring catheter 1700, there may be a component such as a pusher tube 1750 to exit the anchor 1710, such as 1710.1 and 1710.2, out of the anchoring catheter 1700 at the distal end. The push rod 1750 may be attached to a handle (not shown) to enable an operator, such as a physician, to position the one or more anchors 1710 as appropriate. Arrow 1760 indicates the direction of the push.
Fig. 16B-C illustrate how the anchor catheter 1700 of fig. 16A may operate. In fig. 16B, the anchor catheter 1700 is advanced through the coaptation assistance device 1200 through a slot such as described by 520 in fig. 5A. The anchor catheter 1700 then pierces the tissue 1645. The operator pushes the first anchor 1710.1 out of the anchoring catheter 1700, placing the anchor 1710.1 within the tissue. Once the first anchor 1710.1 is deployed, the remainder of the anchor 1710 is deployed as shown in fig. 16C. In fig. 16C, the anchoring catheter 1700 is pulled out of the tissue after deployment of the first anchor 1710.1 to a second position. At the second position, the anchoring catheter 1700 can deploy the second anchor 1710.2. This process continues until it is desired to secure the coaptation assistance device 1200 to the tissue. After delivery of the last anchor 1710, a cutter (not shown) may be advanced within the anchor catheter 1700 to cut the suture 1720, leaving the anchor 1710.
In some embodiments, anchors 1710 may be radiopaque or they may be covered by radiopaque markers. During the process of delivering anchor 1710, the radiopaque markers can be seen if fluoroscopy is used. This can help space the anchor 1710 around the annulus of the coaptation assistance device 1200.
In some embodiments, the MR is evaluated while the coaptation assistance device 1200 is secured, and the stitch length (pitch) and/or position of the suturing action is determined based on the presence or absence of the MR.
Ridge-free implant with cannula
Fig. 17A illustrates another embodiment of an invertebrate coaptation assistance device 1800. In this embodiment, the support structure 1810 may only move down the ventricular projection 1820. A tube or passageway 1830 may be present around the annular edge of the coaptation assistance device 1800. Instead of utilizing the support structure 1810 to maintain the shape of the coaptation assistance device 1800, the anchor catheter 1850 can be inserted into the tube 1830 as shown in fig. 17B. In fig. 17B, the anchor catheter 1850 may be a deflectable anchor catheter.
Fig. 17B also shows a first site 1860.1 where an anchor such as that described by 1560 in fig. 15A may be delivered. At this point 1860.1 and all of the anchoring points 1860, the tip of the anchor catheter 1850 will be deflected by controls located outside the body. An anchor (not shown) may be delivered to secure the coaptation assistance device 1800 to the tissue. The tip of the anchor catheter 1850 may be radiopaque, which may then be visualized during the anchor delivery procedure. Visualization of the tip may be utilized to position the anchor around the annulus of the coaptation assistance device 1800. Fig. 17B illustrates the first anchoring position 1860.1 and fig. 17C illustrates the second anchoring position 1860.2. After the appropriate number of anchors are delivered, the anchor catheter 1850 is completely withdrawn, as shown in fig. 17D. Finally, the support structure 1810 may be removed, as shown in fig. 17E.
In variations of the embodiment shown in fig. 17A-17E, the support structure 1810 may not be limited to only ventricular projections; it may also be inserted through the cannula 1830 so that the desired shape may be maintained. The support structure may be a shape memory material. Utilizing a support structure around the sleeve 1830 may result in an anchor catheter that has a relatively simple control mechanism compared to the anchor catheter 1850 used for the coaptation assistance device 1800 described in fig. 17A.
It is contemplated that various combinations or subcombinations of the specific features and aspects of the embodiments disclosed above may be made and still fall within one or more of the inventions. In addition, the disclosure herein of any particular feature, aspect, method, property, characteristic, quality, attribute, element, etc. may be used with an embodiment in all other embodiments presented herein. Thus, it should be understood that various features and aspects of the disclosed embodiments can be combined with or substituted for one another in order to form varying modes of the disclosed inventions. Therefore, it is intended that the scope of the invention herein disclosed should not be limited by the particular disclosed embodiments described above. In addition, while the invention is susceptible to various modifications and alternative forms, specific examples thereof have been shown in the drawings and are herein described in detail. It should be understood, however, that the invention is not to be limited to the particular forms or methods disclosed, but to the contrary, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the various embodiments described and the appended claims. Any methods disclosed herein need not be performed in the order recited. The methods disclosed herein include certain actions taken by a practitioner; however, they may also include any third party indication of those behaviors, either explicitly or implicitly. For example, actions such as "insert the coaptation assist body near the mitral valve" include "indicate that the coaptation assist body is inserted near the mitral valve". The ranges disclosed herein also include any or all of the overlaps, sub-ranges, and combinations thereof. Language such as "up to," "at least," "greater than," "less than," "between," and the like includes the recited number. As used herein, numbers preceded by terms such as "about", and "substantially" include the recited number and also indicate amounts which are close to the recited amount yet still perform the desired function or achieve the desired result. For example, the terms "about", and "substantially" can refer to an amount within a range of no more than less than 10% of the amount, no more than less than 5% of the amount, no more than less than 1% of the amount, no more than less than 0.1% of the amount, no more than less than 0.01% of the amount.

Claims (21)

1. An anchoring system, the anchoring system comprising:
an implant having a site through which a helical tissue anchor may pass;
the helical tissue anchor;
a first engagement structure on the helical tissue anchor for releasably engaging a torque shaft, wherein the torque shaft is torqueable and deflectable; and
a second engagement structure on the torque shaft for engaging the helical tissue anchor;
wherein the torque shaft is configured to rotate to drive the helical tissue anchor into tissue and secure the implant to tissue,
wherein the first engagement structure is an aperture and the second engagement structure is a protrusion, wherein the protrusion is laterally movable into and out of the aperture in response to axial movement of an elongate element within the torque shaft.
2. The anchoring system of claim 1, wherein the helical tissue anchor comprises a shoulder having the aperture extending therethrough.
3. The anchoring system of claim 1, wherein the helical tissue anchor comprises a fluorescent marker.
4. The anchoring system of claim 1, wherein the implant comprises a coaptation assist body, wherein the coaptation assist body comprises a first coaptation surface, wherein the coaptation assist body comprises a second coaptation surface opposite the first coaptation surface, wherein the first and second coaptation surfaces are bounded by a first lateral edge, a second lateral edge, a lower edge, and an upper edge.
5. The anchoring system of claim 1, wherein the implant comprises a support structure made of a shape memory material.
6. The anchoring system of claim 1, wherein the implant comprises a support structure, wherein the support structure comprises a passive hook.
7. The anchoring system of claim 1, further comprising a commissural anchor.
8. The anchoring system of claim 1, wherein the implant comprises a support structure having a first segment and a second segment, wherein the first segment extends from a position between an upper edge and a lower edge of the coaptation assist body, wherein the second segment extends past at least a portion of the coaptation assist body between the first lateral edge and the second lateral edge.
9. The anchoring system of claim 1, wherein the body of the implant comprises a biocompatible material.
10. The anchoring system of claim 1, wherein the body of the implant comprises ePTFE.
11. The anchoring system of claim 1, wherein the body of the implant is coupled to a support structure such that the shape of the support structure imparts a general shape to the implant.
12. An anchoring system, comprising:
a helical tissue anchor, the helical tissue anchor comprising:
a shoulder having a bore extending therethrough;
a helical structure extending distally from the shoulder;
a first engagement structure on the helical tissue anchor for releasably engaging a torque shaft, wherein the torque shaft is torqueable and deflectable;
a second engagement structure on the torque shaft for engaging the helical tissue anchor; and
an implant having a site through which the helical tissue anchor can pass;
wherein the torque shaft is configured for rotation to drive the helical anchor into tissue and secure the implant to tissue,
wherein the first engagement structure is an aperture and the second engagement structure is a protrusion, wherein the protrusion is laterally movable into and out of the aperture in response to axial movement of an elongate element within the torque shaft.
13. The anchoring system of claim 12, wherein the helical tissue anchor includes a fluorescent marker.
14. The anchoring system of claim 12, wherein the implant comprises a coaptation assist body, wherein the coaptation assist body comprises a first coaptation surface, wherein the coaptation assist body comprises a second coaptation surface opposite the first coaptation surface, wherein the first and second coaptation surfaces are bounded by a first lateral edge, a second lateral edge, a lower edge, and an upper edge.
15. The anchoring system of claim 12, wherein the implant comprises a support structure made of a shape memory material.
16. The anchoring system of claim 12, wherein the implant comprises a support structure, wherein the support structure comprises a passive hook.
17. The anchoring system of claim 12, further comprising a commissural anchor.
18. The anchoring system of claim 12, wherein the implant comprises a support structure having a first segment and a second segment, wherein the first segment extends from a position between an upper edge and a lower edge of the coaptation assist body, wherein the second segment extends past at least a portion of the coaptation assist body between the first lateral edge and the second lateral edge.
19. The anchoring system of claim 12, wherein the body of the implant comprises a biocompatible material.
20. The anchoring system of claim 12, wherein the body of the implant comprises ePTFE.
21. The anchoring system of claim 12, wherein the body of the implant is coupled to a support structure such that the shape of the support structure imparts a general shape to the implant.
CN201580044329.0A 2014-06-18 2015-06-17 Mitral valve implant for treating valvular regurgitation Active CN106572910B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110375324.3A CN113081393A (en) 2014-06-18 2015-06-17 Mitral valve implant for treating valvular regurgitation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461014060P 2014-06-18 2014-06-18
US61/014,060 2014-06-18
PCT/US2015/036260 WO2015195823A1 (en) 2014-06-18 2015-06-17 Mitral valve implants for the treatment of valvular regurgitation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110375324.3A Division CN113081393A (en) 2014-06-18 2015-06-17 Mitral valve implant for treating valvular regurgitation

Publications (2)

Publication Number Publication Date
CN106572910A CN106572910A (en) 2017-04-19
CN106572910B true CN106572910B (en) 2021-04-27

Family

ID=58518582

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580044329.0A Active CN106572910B (en) 2014-06-18 2015-06-17 Mitral valve implant for treating valvular regurgitation
CN202110375324.3A Pending CN113081393A (en) 2014-06-18 2015-06-17 Mitral valve implant for treating valvular regurgitation

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110375324.3A Pending CN113081393A (en) 2014-06-18 2015-06-17 Mitral valve implant for treating valvular regurgitation

Country Status (1)

Country Link
CN (2) CN106572910B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022523456A (en) * 2019-01-14 2022-04-25 エムテックス カーディオ アーゲー Heart valve apex coapter
US20200268371A1 (en) * 2019-02-27 2020-08-27 Covidien Lp Purse string suture device

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951603A (en) * 1997-09-25 1999-09-14 Johnson & Johnson Professional, Inc. Rotatable joint prosthesis with axial securement
CN103338726A (en) * 2011-01-28 2013-10-02 中峰医疗公司 Coaptation enhancement implant, system and method
CN103547237A (en) * 2011-05-18 2014-01-29 欧利奇两合股份有限公司 Prosthetic spinal disk
CN104582637A (en) * 2012-06-22 2015-04-29 中峰医疗公司 Device, system, and method for transcatheter treatment of valve regurgitation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070118151A1 (en) * 2005-11-21 2007-05-24 The Brigham And Women's Hospital, Inc. Percutaneous cardiac valve repair with adjustable artificial chordae
US20070185571A1 (en) * 2006-02-06 2007-08-09 The Cleveland Clinic Foundation Apparatus and method for treating a regurgitant valve
US9011530B2 (en) * 2008-12-22 2015-04-21 Valtech Cardio, Ltd. Partially-adjustable annuloplasty structure
US8545553B2 (en) * 2009-05-04 2013-10-01 Valtech Cardio, Ltd. Over-wire rotation tool
US8940044B2 (en) * 2011-06-23 2015-01-27 Valtech Cardio, Ltd. Closure element for use with an annuloplasty structure
CA3050297A1 (en) * 2009-11-05 2011-05-12 The Trustees Of The University Of Pennsylvania Valve prosthesis
WO2011111047A2 (en) * 2010-03-10 2011-09-15 Mitraltech Ltd. Prosthetic mitral valve with tissue anchors
SE535690C2 (en) * 2010-03-25 2012-11-13 Jan Otto Solem An implantable device and cardiac support kit, comprising means for generating longitudinal movement of the mitral valve
US8888843B2 (en) * 2011-01-28 2014-11-18 Middle Peak Medical, Inc. Device, system, and method for transcatheter treatment of valve regurgitation
US9474605B2 (en) * 2012-05-16 2016-10-25 Edwards Lifesciences Corporation Devices and methods for reducing cardiac valve regurgitation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951603A (en) * 1997-09-25 1999-09-14 Johnson & Johnson Professional, Inc. Rotatable joint prosthesis with axial securement
CN103338726A (en) * 2011-01-28 2013-10-02 中峰医疗公司 Coaptation enhancement implant, system and method
CN103547237A (en) * 2011-05-18 2014-01-29 欧利奇两合股份有限公司 Prosthetic spinal disk
CN104582637A (en) * 2012-06-22 2015-04-29 中峰医疗公司 Device, system, and method for transcatheter treatment of valve regurgitation

Also Published As

Publication number Publication date
CN106572910A (en) 2017-04-19
CN113081393A (en) 2021-07-09

Similar Documents

Publication Publication Date Title
JP7247132B2 (en) Mitral valve implant for treatment of valvular regurgitation
JP7004765B2 (en) Systems and methods for implant fixation
US11000372B2 (en) Systems and methods for transcatheter treatment of valve regurgitation
EP3370650B1 (en) Device and system for transcatheter treatment of valvular regurgitation
EP2249711B1 (en) Multi-window guide tunnel
CN110913801A (en) Devices, systems, and methods for transcatheter treatment of valve regurgitation
CN106572910B (en) Mitral valve implant for treating valvular regurgitation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: California, USA

Applicant after: Boraris Medical Co., Ltd

Address before: California, USA

Applicant before: Middle Peak Medical Inc

GR01 Patent grant
GR01 Patent grant